Vyleesi Microdosing Protocols: What the Evidence Actually Shows

What Is Bremelanotide and Why Microdosing Comes Up

Bremelanotide (brand name Vyleesi) is a melanocortin receptor agonist approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts on MC3R and MC4R receptors in the central nervous system to modulate sexual desire pathways, distinguishing it mechanistically from flibanserin (Addyi), which targets serotonin and dopamine receptors 1.

The approved 1.75 mg dose produces meaningful clinical benefit. The problem: roughly 40% of women in the key RECONNECT trials experienced nausea, and about 20% reported flushing 1. Those rates are high enough that a meaningful portion of patients discontinue the drug before achieving benefit. That tolerability gap is precisely why clinicians and compounding pharmacies have started asking whether a lower starting dose, often called a microdose, could preserve efficacy while reducing adverse events.

How Bremelanotide Works at the Receptor Level

Bremelanotide is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). After subcutaneous injection, it reaches peak plasma concentration in roughly 1 hour and has a terminal half-life of approximately 2.7 hours 2. Its agonism at MC4R in the hypothalamus is thought to be the primary driver of pro-sexual CNS signaling, though the exact pathway is not fully characterized.

Because the dose-response curve for melanocortin agonists is steep in animal models, small reductions in dose may shift the balance between CNS efficacy and peripheral side effects, including nausea (driven partly by MC1R and MC3R activation in the gut) and flushing (driven by vasodilation). That pharmacology is the theoretical rationale for microdosing, even though no human dose-finding study below 1.75 mg has been published.

Regulatory History and the 1.75 mg Selection

The FDA approved 1.75 mg based on the RECONNECT program. Earlier phase 2 studies tested doses from 0.75 mg to 3.0 mg. At 0.75 mg, the efficacy signal was weaker. At 3.0 mg, adverse events became unacceptable. The 1.75 mg dose represented the inflection point in the benefit-risk curve as assessed by the agency 2. No sub-1.75 mg dose was formally included in the key phase 3 program, leaving a real evidence gap that off-label microdosing attempts to fill.

The RECONNECT Trials: The Only Key Evidence Base

The RECONNECT program (two parallel phase 3 RCTs, RECONNECT A and RECONNECT B) enrolled a combined N=1,247 premenopausal women with generalized, acquired HSDD. Results were published in Obstetrics and Gynecology in 2019 1. This is the data set that defines what we know about bremelanotide's efficacy and safety profile.

Primary Efficacy Endpoints

RECONNECT used two co-primary endpoints measured over 24 weeks: change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score (desire-related distress subscale) and change from baseline in the Female Sexual Function Index (FSFI) desire domain score.

In both trials combined, women randomized to bremelanotide 1.75 mg showed a statistically significant improvement on both co-primary endpoints versus placebo (P<0.001) 1. The mean change in FSDS-DAO desire distress subscale was approximately -12 points with bremelanotide versus approximately -7 points with placebo, a clinically meaningful separation. The FSFI desire domain improved by roughly 0.6 points more in the active arm than placebo, which is modest in absolute terms but consistent with what the field has accepted as meaningful for HSDD pharmacotherapy.

Adverse Event Profile That Motivates Microdosing

Nausea was reported in approximately 40% of bremelanotide-treated women versus 1% of placebo recipients 1. Flushing occurred in roughly 20% versus 2%. Headache was reported by about 11% of the active group. Injection-site reactions (bruising, pain) were common but generally mild.

A transient increase in mean arterial pressure, averaging 3 to 4 mmHg and peaking within 2 hours of injection, was observed. This returns to baseline within 12 hours in most women, but the FDA label carries a warning to avoid bremelanotide in patients with uncontrolled hypertension or known cardiovascular disease 2.

Nausea severity appeared dose-related in phase 2 data, which is the strongest mechanistic argument for trialing lower doses. The prescribing information recommends antiemetic pretreatment with ondansetron if nausea is anticipated 2.

What RECONNECT Does Not Tell Us About Microdosing

RECONNECT was not designed to answer microdosing questions. The trial used a fixed 1.75 mg dose and did not include dose-titration arms or sub-therapeutic comparators. Any claim that a 0.5 mg, 0.75 mg, or 1.25 mg dose produces comparable efficacy to 1.75 mg is extrapolation, not trial evidence.

Off-Label Microdosing: What Is Happening in Practice

No peer-reviewed publication has reported outcomes from a prospective cohort or RCT of bremelanotide doses below 1.75 mg in humans. What exists is a growing off-label practice driven by compounding pharmacies, driven primarily by the tolerability problem.

Dose Ranges Being Used Off-Label

Clinicians prescribing compounded bremelanotide report starting some patients at 0.5 mg or 0.75 mg subcutaneous, injecting the same way as the branded product, approximately 45 minutes before anticipated activity. The rationale is a stepped approach: begin low, assess tolerability and response, and titrate up toward 1.75 mg only if needed. Some patients, in clinical observation, report adequate subjective benefit at 1.0 to 1.25 mg with substantially reduced nausea.

A practical titration framework used by some HealthRX-affiliated providers runs as follows. Week 1 to 2: 0.5 mg compounded subcutaneous, used no more than twice in the first two weeks to establish tolerability. Week 3 to 4: if nausea is absent or mild and desire improvement is insufficient, increase to 1.0 mg per use. Week 5 onward: if response remains inadequate, titrate to the FDA-approved 1.75 mg, with ondansetron 4 mg oral or sublingual taken 30 minutes before injection if prior nausea was bothersome. This framework is based on pharmacokinetic reasoning and clinical judgment, not published trial data.

Compounding Considerations

Branded Vyleesi comes as a single-dose autoinjector prefilled at 1.75 mg per 0.3 mL. Doses below 1.75 mg require a compounding pharmacy that can prepare bremelanotide at a specified concentration for subcutaneous injection. Patients and prescribers should confirm that any compounding pharmacy used is compliant with USP 797 sterile compounding standards 3.

Quality control matters here. Peptide stability, pH, and sterility vary across compounders. Prescribers should request certificates of analysis and confirm the pharmacy's sterility testing protocols before initiating a compounded bremelanotide regimen.

Theoretical Pharmacologic Support

The dose-response relationship for melanocortin receptor agonists in humans is not linear across all outcomes. In a 2008 phase 2 dose-escalation study (N=396 women with female sexual dysfunction), bremelanotide at doses of 0.75 mg, 1.25 mg, and 1.75 mg all showed dose-dependent increases in satisfying sexual events versus placebo 4. The 0.75 mg group showed a statistically significant improvement on at least one endpoint versus placebo (P<0.05), suggesting CNS target engagement at sub-1.75 mg doses occurs. This does not prove equivalent efficacy, but it does support the idea that lower doses are not pharmacologically inert.

Safety Considerations Specific to Dose Reduction

Cardiovascular Signal at Lower Doses

The transient blood pressure rise seen at 1.75 mg appears to be dose-related across the phase 2 program. At 0.75 mg, the mean arterial pressure increase was smaller in magnitude, though still detectable 4. This is relevant for patients with borderline hypertension. The FDA label contraindicates bremelanotide in patients with uncontrolled hypertension, and that contraindication applies regardless of dose because the cardiovascular effect has not been formally studied at sub-1.75 mg doses in a powered safety cohort 2.

Blood pressure monitoring before and approximately 90 minutes after the first use, at any dose, is a reasonable clinical practice.

Hyperpigmentation Risk

Focal hyperpigmentation of the face, breasts, and gums has been reported with bremelanotide, likely due to MC1R agonism in melanocytes 2. The FDA label notes this occurs more commonly with more than eight doses per month. Whether lower doses reduce this risk is plausible but unproven. Patients with darker baseline skin tones or personal or family history of pigmentation disorders warrant specific counseling.

Drug Interactions

Bremelanotide slows gastric emptying, which may reduce the oral absorption rate of co-administered medications. The label specifically notes that naltrexone absorption may be reduced 2. For patients on oral naltrexone (for alcohol use disorder or low-dose naltrexone regimens), timing bremelanotide injection at least 4 hours away from the naltrexone dose is advisable. This gastric-emptying effect may be somewhat attenuated at lower doses, though no pharmacokinetic study has confirmed that.

Patient Selection and Clinical Decision Points

Who Might Benefit From a Microdose Start

Women who meet diagnostic criteria for HSDD per the DSM-5 (marked decrease in sexual desire causing distress, not explained by relationship problems, other mental health conditions, or medications) and who want pharmacotherapy but have significant nausea concerns are the most plausible candidates for a microdose titration approach 5.

Specific populations include women who previously discontinued Vyleesi due to nausea at 1.75 mg, women with baseline nausea from other causes (e.g., hormonal contraceptives or thyroid dysfunction), and women who weigh below 55 kg, where standard dosing may produce proportionally higher plasma exposures. None of these indications are label-supported, and prescribers should document the clinical rationale thoroughly.

Who Should Not Use Bremelanotide at Any Dose

The FDA label carries clear contraindications regardless of dose 2:

• Uncontrolled hypertension (blood pressure consistently above 140/90 mmHg)
• Known cardiovascular disease, including history of stroke or coronary artery disease
• Postmenopausal status (approved only for premenopausal women)

These contraindications are not mitigated by dose reduction. A patient with uncontrolled hypertension and HSDD should receive blood pressure optimization first and bremelanotide consideration only after cardiovascular risk is addressed.

HSDD Diagnosis Requires Ruling Out Reversible Causes

Before prescribing bremelanotide at any dose, clinicians should confirm that reversible contributors to low sexual desire have been assessed. Per the American College of Obstetricians and Gynecologists guidance, this includes evaluation of testosterone levels, thyroid function, prolactin, estrogen status, relationship factors, and medication review (SSRIs, antihypertensives, and hormonal contraceptives are common desire suppressants) 6.

The Decreased Sexual Desire Screener (DSDS) is a validated 5-item tool that takes under 2 minutes to administer and has been endorsed in HSDD literature for distinguishing generalized from situational desire problems 7.

Comparing Bremelanotide to Flibanserin in the Context of Dosing Flexibility

Flibanserin (Addyi, 100 mg oral daily) is the other FDA-approved HSDD medication. Unlike bremelanotide, it requires daily dosing rather than as-needed use 8. That daily requirement makes dose titration for tolerability more practically feasible since plasma steady state can be monitored over weeks. Bremelanotide's as-needed design means each use is an acute pharmacokinetic event, and dose adjustments directly and immediately affect both efficacy and side-effect exposure with each encounter.

A 2019 meta-analysis in the Journal of Sexual Medicine (N=4,157 across included trials) found that both agents produced statistically significant but modest improvements in desire scores and satisfying sexual events versus placebo, with neither showing a clearly superior benefit-to-risk ratio across all patient subgroups 9. The choice between them in practice often comes down to patient preference for daily versus as-needed dosing and individual tolerability profiles rather than efficacy magnitude.

Practical Prescribing Guidance for Clinicians

Initiating Vyleesi at the Approved 1.75 mg Dose

The standard approach, based on the FDA-approved label, is to prescribe branded Vyleesi 1.75 mg autoinjector, with the following instructions 2:

• Inject subcutaneously into the abdomen or thigh, not the upper arm
• Inject approximately 45 minutes before anticipated sexual activity
• Do not use more than once in any 24-hour period
• Limit use to 8 doses or fewer per month due to hyperpigmentation risk
• Take ondansetron 4 mg 30 minutes before injection if nausea was problematic on a prior dose

The first injection should ideally occur in a clinical or supervised setting so blood pressure can be checked at baseline and 90 minutes post-injection.

Documenting Off-Label Microdose Decisions

If a clinician elects to prescribe compounded bremelanotide at a sub-1.75 mg dose, documentation should include the following elements: confirmed HSDD diagnosis with distress criterion met, prior trial of 1.75 mg with intolerable nausea or specific contraindication to standard dose, written patient counseling that lower doses lack RCT efficacy data, baseline blood pressure, and a defined titration plan with endpoints for reassessment at 4 and 8 weeks.

This documentation serves both clinical and medicolegal purposes. As the American Society for Reproductive Medicine notes in its position on compounded hormones and peptides, off-label use carries prescriber responsibility for informed consent and outcome tracking 10.

Monitoring Parameters During Microdose Titration

Blood pressure should be checked at the first use of each new dose level. Patients should report any onset of new facial, breast, or gum hyperpigmentation. A symptom diary using a validated tool, the FSFI desire subscale or the DSDS, administered at baseline, week 4, and week 8, gives structured outcome data to guide the titration decision. If desire improvement is absent after 4 weeks at a given dose and tolerability allows, titration to the next dose level or to 1.75 mg is appropriate.